WHAT IS PHARMACOGENETICS, OR IS IT PHARMACOGENOMICS?
Some key terms in this field are defined in Table 1. 1,2 DNA polymorphisms are the unique changes in DNA sequence that are considered to be the mediators of variations in drug response to treatment, susceptibility to disease, and other differences among individuals. Single nucleotide polymorphisms (SNPs) are the most common type of DNA variation, and are intensely investigated as causes of variations in drug responsivity among individuals (Table 1) . 
Key Terms 1,2
Term Definition DNA Nucleic acids that store genetic "blueprints;" there are 3 billion pairs of nucleotide bases in the human genome Gene Region of DNA sequence; regulates a n d / o r t r a n s l a t e s i n t o f u n c t i o n ; heritable; estimated >10,000 genes on 23 pairs of chromosomes in humans Figure 1 attempts to show the link between a gene and drug response. 3 Therefore, the specific type of gene that an individual expresses will dictate the molecular subtype of protein that gene expresses. Depending upon subtle molecular variations in that protein (eg, for an enzyme, receptor, or growth factor), this hypothetically alters the efficiency of information processing in brain circuits and, thus, dictates differences in behaviors mediated by those circuits. 3 Changing neurotransmission at these circuits with drugs acting by specific mechanisms may have different functional interactions within these circuits; this can theoretically determine whether the drug alters information 
Examples of Pharmacogenomics in Medicine
Warfarin • Warfarin's mechanism of anticoagulant action is inhibition of the enzyme that recycles vitamin K (VKORC1) • 60% of anticoagulant drug response to warfarin depends upon which genetic variant a patient has for VKORC1 and also for CYP 2C9 • FDA highlights the use of tests for these genetic variants to predict reasonable (and thus safe as well as effective) doses of warfarin for individual patients
Pertuzumab (Herceptin)
• Pertuzumab is the humanized monoclonal antibody to the human epidermal growth factor receptor or HER2 and its mechanism of anti-cancer action is to bind to HER2/neu receptor to reduce tumor growth • HER2 overexpression predicts poor disease outcome for breast cancer and pertuzumab reduces relapse and mortality in HER2 positive tumors but no benefits for HER2 positive tumors • FDA recommends drug use only for patients whose tumors are HER2 positive (30% to 40% of all breast cancers) to avoid unnecessary exposure to cardiac toxicity and unnecessary expense in patients destined not to respond processing there and, subsequently, whether it works to reduce symptoms. [1] [2] [3] A l t h o u g h s o m e e x p e rt s u s e t h e t e r m s "pharmacogenetics" and "pharmacogenomics" interchangeably, many consider pharmacogenetics to be the study of specific SNPs at specific genes with known functions that could plausibly be linked to drug response, whereas pharmacogenomics scans the whole human genome to find SNPs empirically associated with a drug response, without necessarily knowing the function of the SNP (Table 2) . 1, 2 Pharmacogenetics tests SNPs identified in advance, such as those linked to various neurotransmitters, receptors, or growth factors, whereas pharmacogenomics scans the entire genome to determine SNPs that are associated with drug response and often identifies genes whose functions are not known or would not have been predicted in advance to be linked to drug response.
In either case, SNPs (on the left in Figure 2 ) alter protein synthesis by making subtle molecular changes in the amino acid sequence of these proteins (middle of Figure 2 ), hypothetically leading to changes within brain circuits that alter function, including causing symptoms of psychiatric disorders. 3 SNPs may also determine whether these circuits will respond to specific drugs by determining the capability of various molecular targets within specific brain circuits to alter the efficiency of information processing and thereby reduce psychiatric symptoms (on the right in Figure 2 ; Figure 1 ).
CONCLUSION

Status of Pharmacogenomics in Medicine Today
Several examples exist where knowing which genetic variant of specific genes that a (Table 3) . 1, 4 What about psychiatry? Can pharmacogenomics lead to individualized treatments for psychiatric disorders (Figure 3) ? Some of the key challenges to implementing clinically useful pharmacogenomics in psychiatry today are listed in Table  4 and include the fact that there are generally only preliminary and unconfirmed results for many specific genes with hypothesized links to drug response (Table 5) . [5] [6] [7] [8] However, the promising leads shown in Table 5 , coupled with proven advances in other fields (Table 3 ) pave the way for psychiatry. Soon there may be clinically applicable pharmacogenomic markers for psychopharmacologic management.
The key question we want answered is: "Does testing for genetic polymorphisms in subjects undergoing psychiatric drug treatment lead to improvement in outcome, or are testing results useful in medical, personal, or public health decision making?" 1 When that answer is "yes, " pharmacogenomics will come of age in psychiatry. Until then, stay tuned and stay informed. CNS
